{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:16:27Z","timestamp":1783041387536,"version":"3.54.6"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013840","name":"Biocenter Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM139583"],"award-info":[{"award-number":["R35GM139583"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109912","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:15:37Z","timestamp":1776957337000},"page":"109912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["4-Anilinoquinazoline carbamate derivatization as a platform for prodrug design and localized drug delivery"],"prefix":"10.1016","volume":"178","author":[{"given":"Mabel Barreiro","family":"Carpio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleman D.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Fikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomo","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alejandro","family":"Valdes-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Gani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Mallory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.M.","family":"Asquith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeny","family":"Brudno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua G.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109912_bb0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109912_bb0010","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1039\/D3RA02347H","article-title":"Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review","volume":"13","author":"Mansour","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.109912_bb0015","doi-asserted-by":"crossref","first-page":"1700514","DOI":"10.1183\/13993003.00514-2017","article-title":"EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice","volume":"50","author":"Tomasini","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bioorg.2026.109912_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114856","article-title":"Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors","volume":"244","author":"Dou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the EGFR signaling pathway in cancer therapy: Whats new in 2023? HHS public access","volume":"27","author":"Halder","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2026.109912_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-30258-y","article-title":"Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors","volume":"13","author":"Beyett","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109912_bb0035","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1021\/acs.jmedchem.5c01305","article-title":"Elucidating molecular mechanisms of drug-induced hepatotoxicity of lapatinib","volume":"15","author":"Yu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105787","article-title":"Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R\/T790M, and L858R\/T790M\/C797S forms of EGFR","volume":"147","author":"Todsaporn","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bioorg.2026.109912_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102824","article-title":"Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development","volume":"130","author":"Corvaja","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2026.109912_bb0050","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jtho.2017.06.017","article-title":"Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance","volume":"12","author":"Wang","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2026.109912_bb0055","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1021\/acs.jmedchem.3c00277","article-title":"Discovery of potent and wild-type-sparing fourth-generation EGFR inhibitors for treatment of Osimertinib-resistance NSCLC","volume":"66","author":"Dong","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0060","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14517","article-title":"EGFR degraders in non-small-cell lung cancer: breakthrough and unresolved issue","volume":"103","author":"Shen","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109912_bb0065","first-page":"1","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109912_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55378-5","article-title":"Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment","volume":"16","author":"Alsaed","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109912_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106138","article-title":"Design, synthesis and biological evaluation of novel tumor hypoxia-activated EGFR tyrosine kinase inhibitors","volume":"129","author":"Jia","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0080","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Sunder","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bioorg.2026.109912_bb0085","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/cts.12957","article-title":"Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis","volume":"14","author":"Yin","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bioorg.2026.109912_bb0090","article-title":"Hydrogel systems for targeted cancer therapy","volume":"11","author":"Li","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bioorg.2026.109912_bb0095","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1021\/acs.molpharmaceut.2c00792","article-title":"Recent advances in boosting EGFR tyrosine kinase inhibitors-based cancer therapy","volume":"20","author":"Pan","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2026.109912_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2025.114103","article-title":"Injectable hydrogel for controlled anlotinib delivery and enhanced anti-tumor therapy in non-small cell lung cancer","volume":"254","author":"Lan","year":"2025","journal-title":"Mater. Des."},{"key":"10.1016\/j.bioorg.2026.109912_bb0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1208\/s12248-012-9330-0","article-title":"Challenges in development of targeted liposomal therapeutics","volume":"14","author":"Sawant","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.bioorg.2026.109912_bb0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bmt.2023.09.001","article-title":"Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment","volume":"5","author":"Elumalai","year":"2024","journal-title":"Biomed. Tech."},{"key":"10.1016\/j.bioorg.2026.109912_bb0115","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14737140.2019.1615890","article-title":"Prodrugs for targeted cancer therapy","volume":"19","author":"Souza","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bioorg.2026.109912_bb0120","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1039\/D2CS00379A","article-title":"Glycosidase activated prodrugs for targeted cancer therapy","volume":"51","author":"Martin","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.109912_bb0125","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/cmdc.201600417","article-title":"Targeting a targeted drug: an approach toward hypoxia-activatable tyrosine kinase inhibitor prodrugs","volume":"11","author":"Karnthaler-Benbakka","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.109912_bb0130","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","article-title":"Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia","volume":"57","author":"Cheng","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bioorg.2026.109912_bb0135","first-page":"9","article-title":"Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents","volume":"2","author":"Ismail","year":"2016","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109912_bb0140","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1021\/acs.jmedchem.8b01213","article-title":"SGC-GAK-1: a chemical probe for cyclin g associated kinase (GAK)","volume":"62","author":"Asquith","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0145","doi-asserted-by":"crossref","first-page":"10194","DOI":"10.1021\/jo7020373","article-title":"The scope and mechanism of phosphonium-mediated SNAr reactions in heterocyclic amides and ureas","volume":"72","author":"Wan","year":"2007","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0150","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1016\/j.bmcl.2016.05.055","article-title":"Antibacterial activities of fluorescent nano assembled triphenylamine phosphonium ionic liquids","volume":"26","author":"Brunel","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109912_bb0160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.actbio.2020.05.033","article-title":"Click cross-linking improves retention and targeting of refillable alginate depots","volume":"112","author":"Moody","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bioorg.2026.109912_bb0165","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1021\/acs.molpharmaceut.1c00535","article-title":"On-demand drug release from click-refillable drug depots","volume":"18","author":"Palvai","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2026.109912_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2025.124299","article-title":"A versatile and efficient method to quantify purity and degree of substitution in alginate derivatives","volume":"369","author":"Barreiro Carpio","year":"2025","journal-title":"Carbohydr. Polym."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109912_bb0175","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2026.109912_bb0180","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bioorg.2026.109912_bb0185","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib)relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109912_bb0190","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-Anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Madhavi Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bioorg.2026.109912_bb0200","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1021\/acs.jmedchem.9b00350","article-title":"Design of a cyclin g associated kinase (GAK)\/epidermal growth factor receptor (EGFR) inhibitor set to interrogate the relationship of EGFR and GAK in chordoma","volume":"62","author":"Asquith","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0205","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/cmdc.201900428","article-title":"Targeting an EGFR water network with 4-Anilinoquin(az)oline inhibitors for chordoma","volume":"14","author":"Asquith","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.109912_bb0210","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: a web-based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0215","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1021\/acs.jctc.4c00205","article-title":"BAT2: an open-source tool for flexible, automated, and low cost absolute binding free energy calculations","volume":"20","author":"Heinzelmann","year":"2024","journal-title":"J Chem Theory Comput"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109912_bb0220","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41598-020-80769-1","article-title":"Automation of absolute protein-ligand binding free energy calculations for docking refinement and compound evaluation","volume":"11","author":"Heinzelmann","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109912_bb0230","doi-asserted-by":"crossref","DOI":"10.1063\/1.2978177","article-title":"Statistically optimal analysis of samples from multiple equilibrium states","volume":"129","author":"Shirts","year":"2008","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bioorg.2026.109912_bb0240","author":"Passaro"},{"key":"10.1016\/j.bioorg.2026.109912_bb0245","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1073\/pnas.1117147109","article-title":"Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates","volume":"109","author":"Santi","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2026.109912_bb0250","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/tvst.7.4.21","article-title":"A controlled release system for long-acting intravitreal delivery of small molecules","volume":"7","author":"Machinaga","year":"2018","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.bioorg.2026.109912_bb0255","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10637-022-01230-w","article-title":"A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin","volume":"40","author":"McLean","year":"2022","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bioorg.2026.109912_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u22122020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109912_bb0265","first-page":"2099","article-title":"PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner","volume":"3","author":"Bos","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109912_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.128536","article-title":"Dynamics and structural study on supercooled liquid and glassy states of lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinases for cancer therapy","volume":"437","author":"Hussan","year":"2025","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.bioorg.2026.109912_bb0275","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1039\/D2CS00673A","article-title":"The design of small-molecule prodrugs and activatable phototherapeutics for cancer therapy","volume":"52","author":"Han","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.109912_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114860","article-title":"Prodrug approaches for the development of a long-acting drug delivery systems","volume":"198","author":"Chien","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.109912_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.bioorg.2026.109912_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2011.02.002","article-title":"Prodrugs for improving tumor targetability and efficiency \u2606","volume":"63","author":"Mahato","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.109912_bb0295","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3390\/pharmaceutics14091908","article-title":"Injectable hydrogel-based combination cancer immunotherapy for overcoming localized therapeutic efficacy","volume":"14","author":"Kim","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.109912_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/polym13040650","article-title":"Injectable hydrogels: from laboratory to industrialization","volume":"13","author":"Alonso","year":"2021","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.bioorg.2026.109912_bb0305","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1039\/c3tb20940g","article-title":"Injectable biodegradable hydrogels: Progress and challenges","volume":"1","author":"Bae","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bioorg.2026.109912_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2024.122144","article-title":"In situ crosslinkable multi-functional and cell-responsive alginate 3D matrix via thiol-maleimide click chemistry","volume":"337","author":"Magalh\u00e3es","year":"2024","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bioorg.2026.109912_bb0315","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1021\/acs.biomac.7b00627","article-title":"Structure and dynamics of alginate gels cross-linked by polyvalent ions probed via solid state NMR spectroscopy","volume":"18","author":"Brus","year":"2017","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.bioorg.2026.109912_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169035","article-title":"Alginate as a promising biopolymer in drug delivery and wound healing: a review of the state-of-the-art","volume":"23","author":"Abourehab","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109912_bb0325","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/polym15041010","article-title":"Rheological and self-healing behavior of hydrogels synthesized from l-lysine-functionalized alginate dialdehyde","volume":"15","author":"Putri","year":"2023","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.bioorg.2026.109912_bb0330","article-title":"Microstructured click hydrogels for cell contact guidance in 3D","volume":"19","author":"Neves","year":"2023","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.bioorg.2026.109912_bb0335","doi-asserted-by":"crossref","first-page":"12431","DOI":"10.1002\/chem.201501727","article-title":"Origin of orthogonality of strain-promoted click reactions","volume":"21","author":"Wagner","year":"2015","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.bioorg.2026.109912_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202003451","article-title":"An activatable Nano-prodrug for treating tyrosine-kinase-inhibitor-resistant non-small cell lung cancer and for optoacoustic and fluorescent imaging","volume":"16","author":"Xie","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.bioorg.2026.109912_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114557","article-title":"A computer-aided, carrier-free drug delivery system with enhanced cytotoxicity and biocompatibility: a universal model for multifunctional lung cancer therapy","volume":"250","author":"Wang","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.bioorg.2026.109912_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109912_bb0355","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/jss.jss_244_22","article-title":"An inclusive exploration of forced degradation analysis of some therapeutic categories of drugs in the last decade","volume":"50","author":"Tuteja","year":"2023","journal-title":"Journal of the Scientific Society"},{"key":"10.1016\/j.bioorg.2026.109912_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109912_bb0365","doi-asserted-by":"crossref","first-page":"1451517","DOI":"10.3389\/fphar.2024.1451517","article-title":"Recent advances and applications of nitroreductase activable agents for tumor theranostic","volume":"15","author":"Shang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109912_bb0370","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.jmedchem.1c02221","article-title":"Rational design for nitroreductase (NTR)-responsive proteolysis targeting chimeras (PROTACs) selectively targeting tumor tissues","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109912_bb0375","first-page":"1","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109912_bb0380","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.109912_bb0385","doi-asserted-by":"crossref","first-page":"15679","DOI":"10.1021\/acs.jmedchem.2c01041","article-title":"Macrocyclization of quinazoline-based EGFR inhibitors leads to exclusive mutant selectivity for EGFR L858R and del19","volume":"65","author":"Amrhein","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104743","article-title":"Design, synthesis and biological evaluation of 2,3-dihydro-[1,4]dioxino[2,3-f]quinazoline derivatives as EGFR inhibitors","volume":"110","author":"Qin","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109912_bb0395","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:32:19Z","timestamp":1783038739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826004487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":76,"alternative-id":["S0045206826004487"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109912","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"4-Anilinoquinazoline carbamate derivatization as a platform for prodrug design and localized drug delivery","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109912"}}